p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2+ breast cancer that limits trastuzumab deruxtecan efficacy
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2026-01-22 10:39:29 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1038/s43018-025-00969-4
文献链接: https://www.nature.com/articles/s43018-025-00969-4
其他信息:
出版社: Springer Science and Business Media LLC
作者: Dong Hu; Xiaoshuang Lyu; Zheqi Li; Prasanna Ekambaram; Anushka Dongre; Tanner Freeman; Marion Joy; Jennifer M. Atkinson; Daniel D. Brown; Zongyou Cai; Neil M. Carleton; Hannah E. Crentsil; John Little; Felicia Kemp; Linda R. Klei; Maria Beecher; Jeff Sperinde; Weidong Huang; Heikki Joensuu; Ashok Srinivasan; Katherine L. Pogue-Geile; Ying Wang; Huichen Feng; Lisa D. Eli; Alshad S. Lalani; Jian Zou; George C. Tseng; Tullia C. Bruno; Adrian V. Lee; Steffi Oesterreich; Norman Wolmark; Carmen J. Allegra; Samuel A. Jacobs; Linda M. McAllister-Lucas; Peter C. Lucas
全文下载地址: https://www.nature.com/articles/s43018-025-00969-4.pdf
